Search research articles
Contact Us
Filters
Showing results (351-360 of 703) with videos related to
Page
of 71
Sort By:
Journal for Immunotherapy of Cancer
|
September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.
Oncotarget
|
November 20, 2020
Detection of <i>BRAF</i> splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies
Michael E Clark, Helen Rizos, Michelle R Pereira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2023
Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma
B Lian, Z Li, N Wu, et al.
The British Journal of Dermatology
|
January 8, 2026
Real-world evaluation of the use of melanoma risk prediction tools by clinicians in Australia: a mixed methods study
Gillian Reyes-Marcelino, Rehana A Salam, David Espinoza, et al.
Cancers
|
July 2, 2021
Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
Tuba N Gide, Inês Pires da Silva, Camelia Quek, et al.
Nature Medicine
|
July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Nature Communications
|
March 8, 2012
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi, Gatien Moriceau, Xiangju Kong, et al.
Cancer Research
|
June 28, 2017
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
Arabella Young, Shin Foong Ngiow, Jason Madore, et al.
The Journal of Pathology. Clinical Research
|
April 19, 2020
Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value
Raymond Barnhill, Pieter-Jan van Dam, Peter Vermeulen, et al.
Nature Medicine
|
June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Page
of 71
Search research articles
Search
Showing results (351-360 of 703) with videos related to
Sort By:
Page
of 71
Journal for Immunotherapy of Cancer
|
September 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047
Meredith M Regan, Paolo A Ascierto, Evan J Lipson, et al.
Oncotarget
|
November 20, 2020
Detection of <i>BRAF</i> splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies
Michael E Clark, Helen Rizos, Michelle R Pereira, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 13, 2023
Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma
B Lian, Z Li, N Wu, et al.
The British Journal of Dermatology
|
January 8, 2026
Real-world evaluation of the use of melanoma risk prediction tools by clinicians in Australia: a mixed methods study
Gillian Reyes-Marcelino, Rehana A Salam, David Espinoza, et al.
Cancers
|
July 2, 2021
Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
Tuba N Gide, Inês Pires da Silva, Camelia Quek, et al.
Nature Medicine
|
July 4, 2019
Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Nature Communications
|
March 8, 2012
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance
Hubing Shi, Gatien Moriceau, Xiangju Kong, et al.
Cancer Research
|
June 28, 2017
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
Arabella Young, Shin Foong Ngiow, Jason Madore, et al.
The Journal of Pathology. Clinical Research
|
April 19, 2020
Replacement and desmoplastic histopathological growth patterns in cutaneous melanoma liver metastases: frequency, characteristics, and robust prognostic value
Raymond Barnhill, Pieter-Jan van Dam, Peter Vermeulen, et al.
Nature Medicine
|
June 8, 2019
Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
Antoni Ribas, Donald Lawrence, Victoria Atkinson, et al.
Page
of 71